Eventide Asset Management, LLC Immunovant, Inc. Transaction History

Eventide Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$15.27 - $19.72 $35.2 Million - $45.4 Million	-2,303,720 Reduced 62.37%	1,390,000 $21.6 Million
Q4 2022 Feb 13, 2023	SELL	$6.59 - $17.75 $11.1 Million - $29.8 Million	-1,678,792 Reduced 31.25%	3,693,720 $65.6 Million
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $2.14 Million - $3.71 Million	422,512 Added 8.54%	5,372,512 $29.6 Million
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $11.1 Million - $18 Million	1,579,006 Added 46.84%	4,950,000 $43 Million
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $8.44 Million - $15.1 Million	897,994 Added 36.31%	3,370,994 $35.6 Million
Q1 2021 May 14, 2021	BUY	$13.08 - $49.6 $20.2 Million - $76.4 Million	1,541,000 Added 165.34%	2,473,000 $39.7 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $6.92 Million - $11.9 Million	306,050 Added 48.89%	932,000 $32.8 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $8.68 Million - $17.8 Million	625,950 New	625,950 $15.2 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.